Top

BMC Cancer

Published in:

01-12-2020 | Care | Research article

SIP SMART: a parallel group randomised feasibility trial of a tailored pre-treatment swallowing intervention package compared with usual care for patients with head and neck cancer

Authors: Roganie Govender, Christina H. Smith, Helen Barratt, Benjamin Gardner, Stuart A. Taylor

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

Dysphagia or difficulty in swallowing affects quality of life for most patients with head and neck cancer. SIP SMART – [Swallowing Intervention Package: Self-Monitoring, Assessment, Rehabilitation Training] aims to improve post-treatment swallowing outcomes through a targeted and tailored pre-treatment intervention. This feasibility study assessed 1) recruitment and retention, 2) patient acceptability of randomisation and participation, 3) patient adherence, and 4) sought to identify a suitable primary outcome for a definitive trial, including sample size estimation.

Methods

This two-arm parallel group non-blinded randomised feasibility trial took place within a head and neck centre at a teaching hospital in London, UK. Patients newly diagnosed with stage III/IV head and neck cancer were recruited and underwent 6-month follow-up. Patients were randomised to SIP-SMART or usual care via an online web-based system. SIP SMART comprised two 45-min consultations including a baseline clinical and instrumental swallowing assessment, relevant educational information, targeted swallowing exercises, and specific behaviour change strategies to increase exercise adherence. Usual care comprised a single session including a baseline clinical assessment and generic information about the likely impact of treatment on swallowing.

Results

A total of 106 patients were identified at pre-screening, 70 were assessed for eligibility. Twenty-six patients did not meet eligibility criteria [0.37, 95% CI 0.27 to 0.49]. Five of 44 [0.11, 95% CI 0.05 to 0.24] eligible patients were not approached by researchers during clinic. Seven [0.18, 95% CI 0.08 to 0.33] of the 39 approached declined participation. Target recruitment (32 consented patients) was achieved within the timeframe. At 6-months 29/32 [0.91, 95% CI 0.76 to 0.97] patients remained in the trial. Acceptability of randomisation and participation in the intervention was favourable, and adherence to the exercises exceeded the pre-defined 35% minimum criterion. The MD Anderson Dysphagia Inventory swallow related quality of life measure was selected as the most suitable primary outcome for sample size estimation. No adverse effects arose from the intervention, or study participation.

Conclusions

A definitive trial of the SIP SMART intervention compared to usual care is feasible and can be undertaken with patients with head and neck cancer treated within the NHS.

Trial registration

ISRCTN40215425, registered retrospectively.

Available only for authorised users

Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, et al. Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev. 2012;38(8):1033–49 http://www.ncbi.nlm.nih.gov/pubmed/22542950.PubMedCrossRef

Wall LR, Ward EC, Cartmill B, Hill AJ. Physiological changes to the swallowing mechanism following (chemo) radiotherapy for head and neck cancer: a systematic review. Dysphagia. 2013;28:481–93.PubMedCrossRef

Pauloski BR, Rademaker AW, Logemann JA, Stein D, Beery Q, Newman L, et al. Pretreatment swallowing function in patients with head and neck cancer. Head Neck. 2000;22(5):474–82 http://www.ncbi.nlm.nih.gov/pubmed/10897107.PubMedCrossRef

Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, et al. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol. 2015:1–13 http://linkinghub.elsevier.com/retrieve/pii/S1040842815001237.

King SN, Dunlap NE, Tennant PA, Pitts T. Pathophysiology of radiation-induced dysphagia in head and neck Cancer. Dysphagia Springer US. 2016;31(3):1–13.

Burkhead LM, Sapienza CM, Rosenbek JC. Strength-training exercise in dysphagia rehabilitation: principles, procedures, and directions for future research. Dysphagia. 2007;22(3):251–65.PubMedCrossRef

Perry A, Cotton S, Kennedy C. Therapeutic exercises for affecting post-treatment swallowing in people treated for advanced-stage head and neck cancers. Cochrane Database Syst Rev. 2016;5 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011112/abstract.

Govender R, Smith CH, Taylor SA, Barratt H, Gardner B. Swallowing interventions for the treatment of dysphagia after head and neck cancer: a systematic review of behavioural strategies used to promote patient adherence to swallowing exercises. BMC Cancer. 2017;17(1):43 http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2990-x.PubMedPubMedCentralCrossRef

Govender R, Wood CE, Taylor SA, Smith CH, Barratt H, Gardner B, et al. Patient experiences of swallowing exercises after head and neck Cancer : a qualitative study examining barriers and facilitators using behaviour change theory. Dysphagia. 2017;32:559–69. https://doi.org/10.1007/s00455-017-9799-x.PubMedPubMedCentralCrossRef

10.

Govender R, Taylor SA, Smith CH, Gardner B. Helping patients with head and neck Cancer understand dysphagia: exploring the use of video-animation. AJSLP. 2019;28(2):697–705 https://doi.org/10.1044/2018_AJSLP-18-0184.PubMed

11.

Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions : the new Medical Research Council guidance. BMJ. 2008;337:979–83.CrossRef

12.

Michie S, Atkins L, West R. The behaviour change wheel - a guide to designing interventions. Great Britain: Silverback Publishing; 2014.

13.

Paleri V, Patterson J, Rousseau N, Moloney E, Craig D, Tzelis D, et al. Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT. Health Technol Assess. 2018;22(16):1–144.PubMedPubMedCentralCrossRef

14.

Govender R, Smith CH, Gardner B, Barratt H, Taylor SA. Improving swallowing outcomes in patients with head and neck cancer using a theory-based pretreatment swallowing intervention package : protocol for a randomised feasibility study. BMJ Open. 2017;7(3):e014167. https://doi.org/10.1136/bmjopen-2016-0141679.PubMedPubMedCentralCrossRef

15.

Lancaster G, Dodd S, Williamson P. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307–12 http://www.ncbi.nlm.nih.gov/pubmed/15189396.CrossRef

16.

Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82(11):1783–8.PubMedPubMedCentralCrossRef

17.

Mortensen HR, Jensen K, Aksglæde K, Lambertsen K, Eriksen E, Grau C. Prophylactic swallowing exercises in head and neck Cancer radiotherapy. Dysphagia. 2015;30(3):304–14 http://link.springer.com/10.1007/s00455-015-9600-y.PubMedCrossRef

18.

Govender R, Gardner B, Smith CH, Baratt H, Taylor SA. SIP SMART: a parallel group randomised feasibility trial of swallowing prehabilitation for patients with head and neck cancer. BAHNO published conference abstract. J Oral Pathol Med. 2019;48:767–8 https://onlinelibrary.wiley.com/doi/abs/10.1111/jop.12934.

19.

Sullivan GM, Feinn R. Using effect size—or why the P value is not enough. J Grad Med Educ. 2012;4(3):279–82 http://www.jgme.org/doi/abs/10.4300/JGME-D-12-00156.1.PubMedPubMedCentralCrossRef

20.

Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014;50(5):380–6 https://doi.org/10.1016/j.oraloncology.2013.12.019.PubMedPubMedCentralCrossRef

21.

Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014;50(5):387–403 https://doi.org/10.1016/j.oraloncology.2014.01.016.PubMedCrossRef

22.

Tataru D, Mak V, Simo R, Davies EA, Gallagher JE. Trends in the epidemiology of head and neck cancer in London. Clin Otolaryngol. 2016;42(1):104–14.PubMedCrossRef

23.

Csikar J, Aravani A, Godson J, Day M, Wilkinson J. Incidence of oral cancer among south Asians and those of other ethnic groups by sex in West Yorkshire and England, 2001-2006. Br J Oral Maxillofac Surg. 2013;51(1):25–9.PubMedCrossRef

24.

Roland NJ, Paleri V, editors. Head and neck Cancer: multidisciplinary management guidelines. 4th ed. London: ENT UK; 2011.

25.

Patterson JM, Mccoll E, Carding PN, Hildreth AJ, Kelly C, Wilson JA. Swallowing in the first year after chemoradiotherapy for head and neck cancer : clinician- and patient-reported outcomes. Head Neck. 2014;36(3):352–8.PubMedCrossRef

26.

Roe JWG, Drinnan MJ, Carding PN, Harrington KJ, Nutting CM. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia? Oral Oncol. 2014;50(12):1182–7 http://linkinghub.elsevier.com/retrieve/pii/S136883751400270X.PubMedCrossRef

27.

Ringash J, Bezjak A, O’Sullivan B, Redelmeier DA. Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients. Qual Life Res. 2004;13(4):725–33 http://link.springer.com/10.1023/B:QURE.0000021703.47079.46.PubMedCrossRef

28.

Hutcheson K, Portwood, M , Lisec A, Barringer DA GK, Lewin JS. What is a clinically relevant difference in MDADI scores between groups of head and neck Cancer patients? Laryngoscope 2016;126(5):1108–1113.

29.

Wells M, King E. Patient adherence to swallowing exercises in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2017;25(3):175–81 http://insights.ovid.com/crossref?an=00020840-900000000-99360.PubMedPubMedCentralCrossRef

30.

Krekeler BN, Broadfoot CK, Johnson S, Connor NP, Rogus-Pulia N. Patient adherence to dysphagia recommendations: a systematic review. Dysphagia. 2017;33(2):173–84 http://link.springer.com/10.1007/s00455-017-9852-9.PubMedPubMedCentralCrossRef

31.

Greco E, Simic T, Ringash J, Tomlinson G, Inamoto Y, Martino R. Dysphagia treatment for patients with head and neck cancer treated with radiotherapy: a meta-analysis review. Int J Radiat Oncol. 2018;101(2):421–44 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0360301618302219.CrossRef

Title: SIP SMART: a parallel group randomised feasibility trial of a tailored pre-treatment swallowing intervention package compared with usual care for patients with head and neck cancer
Authors: Roganie Govender
Christina H. Smith
Helen Barratt
Benjamin Gardner
Stuart A. Taylor
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Care
Dysphagia
Dysphagia
Dysphagia
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-06877-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

Using digital health to facilitate compliance with standardized pediatric cancer treatment guidelines in Tanzania: protocol for an early-stage effectiveness-implementation hybrid study

microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis

Are cancer patients better off if they participate in clinical trials? A mixed methods study

Long-term sexual functioning in germ-cell tumor survivors

A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Keynote webinar | Spotlight on antibody–drug conjugates in cancer